Chiaojung Jillian Tsai: TACE combined with Lenvatinib and Pembrolizumab vs Placebo for HCC
Chiaojung Jillian Tsai, Lead of the Allan and Ruth Kerbel Palliative RT and Oligomet Program at Princess Margaret Cancer Centre, shared a post on X about a recent paper by Masatoshi Kudo et al. published in The Lancet:
Authors: Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Richard Finn, Josep Llovet et al.
“Genuine question – shouldn’t RT be incorporated in this trial since TACE isn’t the only option (NCCN screenshot below). The PFS of doesn’t seem very impressive and toxicity of the experimental arm is high.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study – The Lancet.”
More posts featuring Chiaojung Jillian Tsai.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023